# A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis

> **NCT04207801** · PHASE2 · COMPLETED · sponsor: **Aurigene Discovery Technologies Limited** · enrollment: 90 (actual)

## Conditions studied

- Chronic Plaque-type Psoriasis

## Interventions

- **DRUG:** AUR101
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT04207801
- **Lead sponsor:** Aurigene Discovery Technologies Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-21
- **Primary completion:** 2021-03-20
- **Final completion:** 2021-04-15
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04207801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04207801, "A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT04207801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*